Feeding soy protein isolate and n-3 PUFA affects polycystic liver disease progression in a PCK rat model of autosomal polycystic kidney disease

J Pediatr Gastroenterol Nutr. 2015 Apr;60(4):467-73. doi: 10.1097/MPG.0000000000000649.

Abstract

Objective: In polycystic liver disease (PCLD), multiple cysts cause liver enlargement, structural damage, and loss of function. Soy protein and dietary ω-3 polyunsaturated fatty acids (n-3 PUFAs) have been found to decrease cyst proliferation and inflammation in polycystic kidney disease. Therefore, the aim of the study was to investigate whether soy protein and n-3 PUFA supplementation attenuates PCLD.

Methods: Young (age 28 days) female PCK rats were fed (n = 12 per group) either casein + corn oil (casein + CO), casein + soybean oil (casein + SO), soy protein isolate + soybean oil (SPI + SO), or SPI + 1:1 soybean/salmon oil blend (SPI + SB) diet for 12 weeks. Liver histology, gene expression by real-time quantitative polymerase chain reaction, and serum markers of liver injury were determined.

Results: Diet had no effect on PCLD progression as indicated by no significant differences in liver weight and hepatic proliferation gene expression between diet groups. PCK rats fed SPI + SB diet, however, had the greatest (P < 0.05) histological evidence of hepatic cyst obstruction, portal inflammation, steatosis, and upregulation (P = 0.03) of fibrosis-related genes. Rats fed SPI + SB diet also had the lowest (P < 0.001) serum cholesterol and higher (P < 0.05) serum alkaline phosphatase and bilirubin concentrations.

Conclusions: Feeding young female PCK rats SPI and n-3 PUFA failed to attenuate PCLD progression. Furthermore, feeding SPI + SB diet resulted in complications of hepatic steatosis attributable to cysts obstruction of bile duct and hepatic vein. Based on the results, it was concluded that diet intervention alone was not effective at attenuating PCLD associated with autosomal recessive polycystic kidney disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alkaline Phosphatase / blood
  • Animals
  • Bile Ducts / drug effects
  • Bile Ducts / pathology
  • Bilirubin / blood
  • Cholesterol / blood
  • Cysts* / drug therapy
  • Cysts* / etiology
  • Diet
  • Dietary Supplements*
  • Disease Progression
  • Fatty Acids, Omega-3 / adverse effects
  • Fatty Acids, Omega-3 / pharmacology*
  • Fatty Acids, Omega-3 / therapeutic use
  • Fatty Liver / blood
  • Fatty Liver / etiology
  • Female
  • Hepatic Veins / drug effects
  • Hepatic Veins / pathology
  • Inflammation / drug therapy
  • Inflammation / etiology
  • Liver / drug effects*
  • Liver Cirrhosis / blood
  • Liver Cirrhosis / etiology
  • Liver Cirrhosis / genetics
  • Liver Diseases* / drug therapy
  • Liver Diseases* / etiology
  • Polycystic Kidney, Autosomal Recessive / drug therapy
  • Polycystic Kidney, Autosomal Recessive / pathology*
  • Rats
  • Soybean Proteins / adverse effects
  • Soybean Proteins / pharmacology*
  • Soybean Proteins / therapeutic use

Substances

  • Fatty Acids, Omega-3
  • Soybean Proteins
  • Cholesterol
  • Alkaline Phosphatase
  • Bilirubin

Supplementary concepts

  • Polycystic liver disease